Compound K Attenuates the Development of Atherosclerosis in ApoE(-/-) Mice via LXRα Activation

Int J Mol Sci. 2016 Jul 8;17(7):1054. doi: 10.3390/ijms17071054.

Abstract

Background: Atherosclerosis is a fundamental pathological process responded to some serious cardiovascular events. Although the cholesterol-lowering drugs are widely prescribed for atherosclerosis therapy, it is still the leading cause of death in the developed world. Here we measured the effects of compound K in atherosclerosis formation and investigated the probably mechanisms of the anti-antherosclerosis roles of compound K.

Methods: We treated the atherosclerotic model animals (apoE(-/-) mice on western diet) with compound K and measured the size of atherosclerotic lesions, inflammatory cytokine levels and serum lipid profile. Peritoneal macrophages were collected in vitro for the foam cell and inflammasome experiments.

Results: Our results show that treatment with compound K dose-dependently attenuates the formation of atherosclerotic plaques by 55% through activation of reverse cholesterol transport pathway, reduction of systemic inflammatory cytokines and inhibition of local inflammasome activity. Compound K increases the cholesterol efflux of macrophage-derived foam cells, and reduces the inflammasome activity in cholesterol crystal stimulated macrophages. The activation of LXRα may contribute to the athero-protective effects of compound K.

Conclusion: These observations provide evidence for an athero-protective effect of compound K via LXRα activation, and support its further evaluation as a potential effective modulator for the prevention and treatment of atherosclerosis.

Keywords: LXRα; atherosclerosis; compound K; inflammasome; reverse cholesterol transport.

MeSH terms

  • Animals
  • Apolipoproteins E / genetics*
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / pathology
  • Caspase 1 / metabolism
  • Cholesterol / blood
  • Cytokines / metabolism
  • Disease Models, Animal
  • Fatty Liver / drug therapy
  • Foam Cells / metabolism
  • Foam Cells / pathology
  • Ginsenosides / pharmacology
  • Ginsenosides / therapeutic use*
  • Liver X Receptors / metabolism*
  • Macrophages, Peritoneal / cytology
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Transcription Factor RelA / metabolism
  • Triglycerides / blood

Substances

  • Apolipoproteins E
  • Cytokines
  • Ginsenosides
  • Liver X Receptors
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Transcription Factor RelA
  • Triglycerides
  • Cholesterol
  • ginsenoside M1
  • Caspase 1